Chemical biosensors for improving drug production

用于改善药物生产的化学生物传感器

• 批准号: 519754-2017
• 负责人: McMillen, David
• 金额: $ 1.82万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=639931
• 关键词: Chemical; biosensors; improving; drug; production

Many pharmaceuticals are complex, natural compounds that can be difficult to extract from their sources or tosynthesize chemically. To overcome this, some pharmaceuticals can be produced in a host organism that iseasier to manage on a commercial scale. Hyasynth Bio has developed strains of yeast that producecannabinoids, a class of compounds with great potential as medicines and therapeutics. Early approvedcannabinoid medicines in Canada include nabiximols, for adjunctive analgesic treatment in adult patients withadvanced cancer, and nabilone, for severe nausea and vomiting associated with cancer chemotherapy. Torapidly screen yeast strains with improved cannabinoid production, a simple way of detecting and quantifyingthese compounds is required. We aim to develop a new means of detecting medicinal cannabinoids to improvetheir commercial production.

许多药物是复杂的天然化合物，难以从其来源中提取或化学合成。为了克服这一点，一些药物可以在更容易以商业规模管理的宿主生物体中生产。Hybryth Bio已经开发出生产类大麻素的酵母菌株，这是一类具有巨大潜力的药物和治疗化合物。加拿大早期批准的大麻素药物包括用于晚期癌症成人患者连续镇痛治疗的纳比昔莫，以及用于癌症化疗相关的严重恶心和呕吐的纳比隆。为了快速筛选具有提高的大麻素产量的酵母菌株，需要一种检测和定量这些化合物的简单方法。我们的目标是开发一种新的检测药用大麻素的方法，以提高其商业化生产。